Endocrine and clinical effects of leuprolide in prostatic cancer

Publisher Website
Google Scholar
Abstract
Subjects (29 human) with metastatic carcinoma of the prostate received daily s.c. injections of leuprolide, a LHRH analog. After transient gonadotropin and androgen stimulation, leuprolide induced long-term suppression of serum testosterone and gonadotropins production. In 25 subjects there was objective disease stabilization or tumor regression. Eleven subjects subsequently relapsed (median = 10 mo.) after initiation of treatment. Except for vasomotor hot flashes, leuprolide appears to be well tolerated by patients with advanced prostatic cancer.